Results 41 to 50 of about 2,911,119 (244)

Modulation of neurotrophic signaling pathways by polyphenols [PDF]

open access: yes, 2015
Polyphenols are an important class of phytochemicals, and several lines of evidence have demonstrated their beneficial effects in the context of a number of pathologies including neurodegenerative disorders such as Alzheimer's and Parkinson's disease. In
Firuzi, Omidreza   +3 more
core   +1 more source

TRK inhibitors in TRK fusion-positive cancers [PDF]

open access: yesAnnals of Oncology, 2019
TRK fusions are oncogenic drivers of various adult and paediatric cancers. The first-generation TRK inhibitors, larotrectinib and entrectinib, were granted landmark, tumour-agnostic regulatory approvals for the treatment of these cancers in 2018 and 2019, respectively.
openaire   +3 more sources

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

open access: yesBMC Cancer, 2022
Background Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors.
James C. H. Yang   +15 more
doaj   +1 more source

Use of Diagnostic Algorithms for NTRK Fusion-Positive Tumors in Pathology Institutes in Switzerland

open access: yeshealthbook TIMES. Oncology Hematology, 2021
In May 2020, larotrectinib (Vitrakvi®) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Holger Moch   +9 more
doaj   +1 more source

Involvement of ras p2I in Neurotrophin-induced Response of Sensory, but Not Sympathetic Neurons [PDF]

open access: yes, 1993
Little is known about the signal transduction mechanisms involved in the response to neurotrophins and other neurotrophic factors in neurons, beyond the activation of the tyrosine kinase activity of the neurotrophin receptors belonging to the trk family.
Barde, Y. A.   +4 more
core   +3 more sources

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability

open access: yesCancer Medicine, 2022
TRK fusions are rare but targetable mutations which occur across a wide variety of cancer types. We report the prevalence of approximately 0.7% for NTRK‐positive colorectal cancer (CRC) by genetically profiling 2519 colonic and rectal tumors.
Hui Wang   +7 more
doaj   +1 more source

A novel inhibitor of p75-neurotrophin receptor improves functional outcomes in two models of traumatic brain injury. [PDF]

open access: yes, 2016
The p75 neurotrophin receptor is important in multiple physiological actions including neuronal survival and neurite outgrowth during development, and after central nervous system injury.
Alam, Antoine   +20 more
core   +1 more source

Canadian consensus on TRK‐inhibitor therapy for NTRK fusion‐positive sarcoma

open access: yesInternational Journal of Cancer, 2021
Malignant sarcomas are rare accounting for
C. Simmons   +8 more
semanticscholar   +1 more source

Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples [PDF]

open access: yes, 2013
Emerging evidence has shown that the tumor microenvironment plays a crucial role in prostate cancer (PCa) development and progression. However, the mechanism(s) through which stromal cells regulate epithelial cells and the differences among prostatic ...
Clemente, Luigi Di   +7 more
core   +1 more source

The Role of Differentially Expressed miRNAs and Potential miRNA-mRNA Regulatory Network in Prostate Cancer Progression and Metastasis [PDF]

open access: yes, 2020
Purpose: Aberrant expression of microRNAs (miRNAs) has been discovered in prostate cancer progression however their function is not well understood, thereby further investigation is required to understand the importance of underlying mechanisms and their
Arisan, E.D.   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy